A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

NCT04919512 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

163

Enrollment

INDUSTRY

Sponsor class

Conditions

Urinary Bladder Neoplasms

Interventions

DRUG: TAR-200
BIOLOGICAL: Cetrelimab

Sponsor

Janssen Research & Development, LLC